TrialAnnals of oncology : official journal of the European Society for Medical Oncology2016

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

E G Chiorean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.